LXEO
Lexeo Therapeutics Inc
$
4.720
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.9653
Open
4.700
VWAP
4.81
Vol
265.47K
Mkt Cap
156.69M
Low
4.570
Amount
1.28M
EV/EBITDA(TTM)
--
Total Shares
33.20M
EV
56.42M
EV/OCF(TTM)
--
P/S(TTM)
--
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.661
+3.24%
--
--
-0.545
-38.78%
--
--
-0.481
-38.69%
Estimates Revision
The market is revising No Change the revenue expectations for Lexeo Therapeutics, Inc. (LXEO) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 66.78%.
EPS Estimates for FY2025
Revise Downward
-14.45%
In Past 3 Month
Stock Price
Go Up
+66.78%
In Past 3 Month
5 Analyst Rating
260.17% Upside
Wall Street analysts forecast LXEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LXEO is 17.00 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
260.17% Upside
Current: 4.720
Low
10.00
Averages
17.00
High
20.00
260.17% Upside
Current: 4.720
Low
10.00
Averages
17.00
High
20.00
Chardan
Geulah Livshits
Buy
downgrade
$22 -> $20
2025-05-12
Reason
Chardan
Geulah Livshits
Price Target
$22 -> $20
2025-05-12
downgrade
Buy
Reason
Chardan analyst Geulah Livshits lowered the firm's price target on Lexeo Therapeutics to $20 from $22 and keeps a Buy rating on the shares. The firm is updating its model following the company's Q1 results, reiterated guidance on its LX2006 and LX2020 programs, as well as its update on its cash position, the analyst tells investors in a research note.
Chardan Capital
Geulah Livshits
Strong Buy
Maintains
$25 → $22
2025-04-08
Reason
Chardan Capital
Geulah Livshits
Price Target
$25 → $22
2025-04-08
Maintains
Strong Buy
Reason
Chardan analyst Geulah Livshits lowered the firm's price target on Lexeo Therapeutics to $22 from $25 and keeps a Buy rating on the shares. The firm cites the company's updated data from its phase 1/2 SUNRISE-FA trial and Weill Cornell's IIT evaluating AAVrh10 GT LX2006 in patients with Friedreich's ataxia cardiomyopathy showing LVMI improvements/stabilization in a majority of patients at 6+ months with frataxin expression in all evaluated pts at 3 months, the analyst tells investors in a research note. The increased probability of success of 55% for LX2006, up from 45%, is offset by more conservative assumptions on earlier programs as the company moves to accelerate pivotal development while maintaining a 2027 runway, the firm adds.
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$23
2025-04-08
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$23
2025-04-08
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$23
2025-03-26
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$23
2025-03-26
Reiterates
Strong Buy
Reason
RBC Capital
Luca Issi
Buy
Maintains
$24 → $20
2025-03-25
Reason
RBC Capital
Luca Issi
Price Target
$24 → $20
2025-03-25
Maintains
Buy
Reason
RBC Capital lowered the firm's price target on Lexeo Therapeutics to $20 from $24 and keeps an Outperform rating on the shares after its Q4 results. The company also shared its first look at PKP2-ACM, and the firm is positive on safety as the drug has been generally well tolerated with no TEAE - Treatment emergent adverse events - which is key given a starting dose that is 40-times higher vs. the highest dose tested so far for Friedreich ataxia, the analyst tells investors in a research note.
Chardan Capital
Geulah Livshits
Strong Buy
Maintains
$25
2025-03-25
Reason
Chardan Capital
Geulah Livshits
Price Target
$25
2025-03-25
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Lexeo Therapeutics Inc (LXEO.O) is -2.00, compared to its 5-year average forward P/E of -3.40. For a more detailed relative valuation and DCF analysis to assess Lexeo Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.40
Current PE
-2.00
Overvalued PE
-1.71
Undervalued PE
-5.08
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.53
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.06
Undervalued EV/EBITDA
-5.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+45.14%
-33.81M
Operating Profit
FY2025Q1
YoY :
+50.61%
-32.66M
Net Income after Tax
FY2025Q1
YoY :
+28.57%
-0.99
EPS - Diluted
FY2025Q1
YoY :
+44.20%
-21.72M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
7.1K
USD
4
6-9
Months
65.8K
USD
5
0-12
Months
113.3K
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
104.8K
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 116.35% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.3M
Volume
2
6-9
Months
598.0K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
2.8K
Volume
Months
6-9
1
350.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
7.1K
USD
4
6-9
Months
65.8K
USD
5
0-12
Months
113.3K
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
104.8K
USD
Months
LXEO News & Events
Events Timeline
2025-07-07 (ET)
2025-07-07
07:03:34
Lexeo Therapeutics announces FDA Breakthrough Therapy Designation for LX2006
2025-06-24 (ET)
2025-06-24
07:35:16
Lexeo announces partnership to develop therapies using non-viral RNA platform
2025-05-27 (ET)
2025-05-27
07:39:06
Lexeo prices 20.8M shares at $2.8825 in private placement
Sign Up For More Events
Sign Up For More Events
News
4.0
07-31BenzingaThis Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
9.0
07-07NASDAQ.COMWhy Lexeo Is Rising In Pre-market?
7.5
06-24NewsfilterLexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics
Sign Up For More News
People Also Watch
MHH
Mastech Digital Inc
7.550
USD
+3.57%
NKTR
Nektar Therapeutics
25.720
USD
+8.98%
BEEP
Mobile Infrastructure Corp
3.730
USD
-1.06%
SCPH
scPharmaceuticals Inc
4.780
USD
-0.42%
STRT
Strattec Security Corp
81.760
USD
+2.91%
ALEC
Alector Inc
2.180
USD
+9.00%
STRO
Sutro Biopharma Inc
0.772
USD
-1.53%
NEGG
Newegg Commerce Inc
91.890
USD
+24.78%
BDSX
Biodesix Inc
0.384
USD
-6.57%
FAQ
What is Lexeo Therapeutics Inc (LXEO) stock price today?
The current price of LXEO is 4.72 USD — it has increased 1.07 % in the last trading day.
What is Lexeo Therapeutics Inc (LXEO)'s business?
What is the price predicton of LXEO Stock?
What is Lexeo Therapeutics Inc (LXEO)'s revenue for the last quarter?
What is Lexeo Therapeutics Inc (LXEO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Lexeo Therapeutics Inc (LXEO)'s fundamentals?
How many employees does Lexeo Therapeutics Inc (LXEO). have?